Melanoma
CME
Jen Wargo, MD, MMSc
Professor, Department of Genomic Medicine, Division of Cancer Medicine, Professor, Department of Surgical Oncology, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Disclosure information not submitted.
Charlotte Ariyan, MD, PhD
Associate Attending, Gastric & Mixed Tumor Service
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Disclosure(s): Amgen Inc. and Merck & Co., Inc.: Consultant (Terminated); Iovance Biotherapeutics: Consultant (Ongoing); pfizer: Ownership Interest (Ongoing)
Michael Postow, MD
Chief, Melanoma Medical Oncology Service
Co-Director, Melanoma Disease Management Team
Memorial Sloan Kettering Cancer Center
Disclosure information not submitted.
To pre-register, please visit: PeerView.com/Melanoma23-Live
This CME/MOC activity is provided by PVI, PeerView Institute for Medical Education.
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.
Key Reasons to Attend
• Understand the overall treatment role of immunotherapy in resectable melanoma (including BRAF-mutated or wild-type disease) as reflected in current guidelines
• Learn how to effectively utilize immunotherapy in the adjuvant setting, including in populations defined by PD-L1 expression or BRAF status
• Get guidance on how to optimize neoadjuvant immunotherapy as a tumor debulking tool and prepare for next steps with innovative combinatorial options
Dinner will be served.